The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by Cantor Fitzgerald on March 21, 2025. The analyst firm set a price target for $0.00 expecting SMMT to fall to within 12 months (a possible -100.00% downside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by Cantor Fitzgerald, and Summit Therapeutics initiated their overweight rating.

There is no last upgrade for Summit Therapeutics

The last downgrade for Summit Therapeutics Inc happened on September 27, 2024 when Citigroup changed their price target from $19 to $23 for Summit Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.

While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a initiated with a price target of $0.00 to $0.00. The current price Summit Therapeutics (SMMT) is trading at is $20.90, which is out of the analyst’s predicted range.